(INCY) Incyte - Ratings and Ratios
JAKAFI, MONJUVI, PEMAZYRE, ICLUSIG, ZYNYZ
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 32.3% |
| Value at Risk 5%th | 48.7% |
| Relative Tail Risk | -8.44% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.11 |
| Alpha | 31.93 |
| CAGR/Max DD | 0.19 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.502 |
| Beta | 0.545 |
| Beta Downside | 0.604 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.50% |
| Mean DD | 21.34% |
| Median DD | 24.09% |
Description: INCY Incyte October 31, 2025
Incyte Corporation (NASDAQ: INCY) is a U.S.–based biopharmaceutical firm that discovers, develops, and commercializes specialty therapeutics across the United States, Europe, Canada, and Japan. Its approved portfolio includes ruxolitinib (JAKAFI/OPZELURA) for myelofibrosis, polycythemia vera and graft-versus-host disease; tafasitamab (MONJUVI/MINJUVI) for relapsed/refractory diffuse large B-cell lymphoma; pemigatinib (PEMAZYRE) for biliary tract cancers; ponatinib (ICLUSIG) for chronic myeloid leukemia and Ph-positive ALL; retifanlimab (ZYNYZ) for Merkel cell carcinoma; and axatilimab (NIKTIMVO) for chronic GVHD, plus a topical ruxolitinib cream for atopic dermatitis. The pipeline spans multiple modalities, including a CDK2 inhibitor for ovarian cancer, a KRAS G12D-targeted agent, and several immunomodulators for dermatologic and neuro-immune disorders.
Key quantitative points (FY 2023, per the company’s 10-K) show total revenue of approximately $2.5 billion, driven largely by JAKAFI and ICLUSIG, with a year-over-year growth rate of ~12 %. R&D expenditure was $720 million, representing roughly 29 % of revenue, underscoring a heavy reinvestment model typical for biotech firms. The JAK-inhibitor market is projected to expand at a CAGR of ~10 % through 2029, providing a favorable macro-trend for Incyte’s core assets, while the broader oncology biotech sector has seen a 15 % increase in M&A activity in 2024, indicating potential partnership or acquisition upside.
For a deeper quantitative assessment of Incyte’s valuation metrics and peer comparison, the ValueRay platform offers a data-driven dashboard worth exploring.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (1.19b TTM) > 0 and > 6% of Revenue (6% = 288.8m TTM) |
| FCFTA 0.19 (>2.0%) and ΔFCFTA 18.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 61.02% (prev 32.07%; Δ 28.95pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 1.25b > Net Income 1.19b (YES >=105%, WARN >=100%) |
| Net Debt (-2.41b) to EBITDA (1.68b) ratio: -1.43 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.19 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (201.4m) change vs 12m ago 2.85% (target <= -2.0% for YES) |
| Gross Margin 91.91% (prev 91.21%; Δ 0.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 84.87% (prev 81.31%; Δ 3.55pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 702.2 (EBITDA TTM 1.68b / Interest Expense TTM 2.27m) >= 6 (WARN >= 3) |
Altman Z'' 4.84
| (A) 0.46 = (Total Current Assets 4.28b - Total Current Liabilities 1.34b) / Total Assets 6.33b |
| (B) -0.01 = Retained Earnings (Balance) -85.5m / Total Assets 6.33b |
| (C) 0.28 = EBIT TTM 1.59b / Avg Total Assets 5.67b |
| (D) -0.04 = Book Value of Equity -70.8m / Total Liabilities 1.68b |
| Total Rating: 4.84 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 90.18
| 1. Piotroski 7.50pt |
| 2. FCF Yield 7.11% |
| 3. FCF Margin 24.87% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda -1.43 |
| 6. ROIC - WACC (= 27.10)% |
| 7. RoE 29.83% |
| 8. Rev. Trend 87.69% |
| 9. EPS Trend 26.92% |
What is the price of INCY shares?
Over the past week, the price has changed by -0.60%, over one month by -4.16%, over three months by +19.33% and over the past year by +46.32%.
Is INCY a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 15
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the INCY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 100.1 | -0% |
| Analysts Target Price | 100.1 | -0% |
| ValueRay Target Price | 113.7 | 13.6% |
INCY Fundamental Data Overview December 27, 2025
P/E Trailing = 17.0237
P/E Forward = 13.2275
P/S = 4.0969
P/B = 4.2395
P/EG = 0.1306
Beta = 0.815
Revenue TTM = 4.81b USD
EBIT TTM = 1.59b USD
EBITDA TTM = 1.68b USD
Long Term Debt = 33.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 10.4m USD (from shortTermDebt, last quarter)
Debt = 41.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.41b USD (from netDebt column, last quarter)
Enterprise Value = 16.83b USD (19.72b + Debt 41.3m - CCE 2.93b)
Interest Coverage Ratio = 702.2 (Ebit TTM 1.59b / Interest Expense TTM 2.27m)
FCF Yield = 7.11% (FCF TTM 1.20b / Enterprise Value 16.83b)
FCF Margin = 24.87% (FCF TTM 1.20b / Revenue TTM 4.81b)
Net Margin = 24.69% (Net Income TTM 1.19b / Revenue TTM 4.81b)
Gross Margin = 91.91% ((Revenue TTM 4.81b - Cost of Revenue TTM 389.4m) / Revenue TTM)
Gross Margin QoQ = 92.75% (prev 92.13%)
Tobins Q-Ratio = 2.66 (Enterprise Value 16.83b / Total Assets 6.33b)
Interest Expense / Debt = 1.43% (Interest Expense 592.0k / Debt 41.3m)
Taxrate = 12.05% (58.1m / 482.3m)
NOPAT = 1.40b (EBIT 1.59b * (1 - 12.05%))
Current Ratio = 3.19 (Total Current Assets 4.28b / Total Current Liabilities 1.34b)
Debt / Equity = 0.01 (Debt 41.3m / totalStockholderEquity, last quarter 4.65b)
Debt / EBITDA = -1.43 (Net Debt -2.41b / EBITDA 1.68b)
Debt / FCF = -2.02 (Net Debt -2.41b / FCF TTM 1.20b)
Total Stockholder Equity = 3.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.78% (Net Income 1.19b / Total Assets 6.33b)
RoE = 29.83% (Net Income TTM 1.19b / Total Stockholder Equity 3.98b)
RoCE = 39.59% (EBIT 1.59b / Capital Employed (Equity 3.98b + L.T.Debt 33.5m))
RoIC = 35.11% (NOPAT 1.40b / Invested Capital 3.98b)
WACC = 8.01% (E(19.72b)/V(19.76b) * Re(8.02%) + D(41.3m)/V(19.76b) * Rd(1.43%) * (1-Tc(0.12)))
Discount Rate = 8.02% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -5.62%
[DCF Debug] Terminal Value 72.21% ; FCFE base≈724.9m ; Y1≈515.4m ; Y5≈276.3m
Fair Price DCF = 26.99 (DCF Value 5.30b / Shares Outstanding 196.3m; 5y FCF grow -33.99% → 3.0% )
EPS Correlation: 26.92 | EPS CAGR: 129.7% | SUE: 4.0 | # QB: 1
Revenue Correlation: 87.69 | Revenue CAGR: 13.03% | SUE: 2.47 | # QB: 5
EPS next Quarter (2026-03-31): EPS=1.61 | Chg30d=-0.015 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=7.66 | Chg30d=-0.088 | Revisions Net=+0 | Growth EPS=+13.7% | Growth Revenue=+11.0%
Additional Sources for INCY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle